A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis

British Journal of Dermatology

Volumn 163, Issue 4, 2010, Pages 807-816

  Fonia, A ^a   Jackson, K ^a   Lereun, C ^b   Grant, D M ^c   Barker, J N W N ^a   Smith, C H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Independent Biostatistician   (Ireland)

^c IQVIA   (United States)

Author keywords

biologic therapy; costs; medical resource use; psoriasis

Indexed keywords

ACICLOVIR; ADALIMUMAB; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; CYCLOSPORIN A; EFALIZUMAB; ERYTHROMYCIN; ETANERCEPT; ETRETIN; FLUCLOXACILLIN; FUMADERM; FUMARIC ACID; HYDROCORTISONE; HYDROXYUREA; INFLIXIMAB; ISONIAZID PLUS RIFAMPICIN; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; AGED; ARTICLE; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; DRUG USE; FEMALE; HOSPITAL COST; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY OF LIFE;

ADULT; AGED; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; EPIDEMIOLOGIC METHODS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LONDON; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77957050592     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09944.x     Document Type: Article

References (20)

1. Griffiths CE, Clark CM, Chalmers RJ et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000 4 : 1 125.
2. Gelfand JM, Weinstein R, Porter SB et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005 141 : 1537 1541.
3. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists' guidelines for biologic interventions in psoriasis 2009. Br J Dermatol 2009 161 : 987 1019.
4. Eedy DJ, Griffiths CEM, Chalmers RJG et al. Care of patients with psoriasis: an audit of U.K. services in secondary care. Br J Dermatol 2009 160 : 557 564.
5. National Institute for Health and Clinical Excellence. Etanercept and Efalizumab for the Treatment of Adults with Psoriasis. NICE Technology Appraisal Guidance 103. 2006; reissued December 2009.
6. National Institute for Health and Clinical Excellence. Ustekinumab for the Treatment of Adults with Moderate to Severe Psoriasis. Final appraisal determination. NICE Technology Appraisal Guidance 180. 2009.
7. Woods AL, Rutter KJ, Gardner LS et al. Inpatient management of psoriasis: a multicentre service review to establish national admission standards. Br J Dermatol 2008 158 : 266 272.
8. British Association of Dermatologists Biologic Interventions Register. Available at: http://www.badbir.org. (last accessed 22 November 2009).
9. World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964. Amended by WMA General Assembly, 2004.
10. Department of Health. NHS Reference Costs 2006-07. Appendix NSRC4: Trusts and PCTs Combined. 1 February 2008.
11. Joint Formulary Committee. British National Formulary, vol. 56. London : British Medical Association and Royal Pharmaceutical Society of Great Britain, 2008.
12. Office for National Statistics. First Release: Consumer Price Indices. Newport, South Wales : ONS, June 2008.
13. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 56 : 31. e1 15.
14. Moore A, Gordon K, Kang S et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007 56 : 598 603.
15. Gisondi P, Cotena C, Tessari G et al. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 2008 22 : 341 344.
16. Esposito M, Mazzotta A, Saraceno R et al. Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis. Int J Immunopathol Pharmacol 2009 22 : 219 225.
17. Kimball AB, Gladman D, Gelfand JM et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008 58 : 1031 1042.
18. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991 90 : 711 716.
19. Gisondi P, Targher G, Zoppini G et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009 51 : 758 764.
20. Reich K, Nestle FO, Wu Y et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol 2007 17 : 381 386.